@ThomasW35874311 Profile picture

Thomas Wu

@ThomasW35874311

I am a doctor

Similar User
Sai-Hong Ignatius Ou photo

@oncoOuLungCA

Fred R. Hirsch photo

@fred_hirsch

Misako Nagasaka photo

@MNagasaka

Joshua Reuss photo

@Joshua_Reuss

Dr. Luis E. Raez photo

@LuisRaezMD

Xiuning Le MD PhD photo

@LeXiuning

LudaBazhenovaMD photo

@LudaBazhenovaMD

JessicaJLinMD photo

@JessicaJLinMD

Daniel Tan photo

@danieltanmd

Tetsuya Mitsudomi photo

@t_mitsudomi

Justin Gainor photo

@JustinGainor

Mark Awad photo

@DrMarkAwad

Martin Reck photo

@MartinReck2

Melina Marmarelis photo

@MMarmarelis

Yasir Yousif Elamin photo

@YYElamin

Our paper just out on Cancer Cell: IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable and more patients without recurrence than that received CCRT. Thanks all investigators from 15 sites in China. It is impossible without their hard works!

Online Now: Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial dlvr.it/T8YhfC

Tweet Image 1


Our Editorial for FLAURA 2 just published @NEJM online. DOI: 10.1056/NEJMe2311559

Tweet Image 1

Thomas Wu Reposted

🎙️ Early undetectable ctDNA during CRT 🔁⬆️OS in #lungcancer‼️@OncoAlert 📌Retro study of 761 blood samples from 139 👥 undergoing RT 🥇🎯: Study on ctDNA during chemoradiotherapy (CRT) in #nonsmall cell lung cancer RESULTs📊 👉ctDNA levels ⬇️ significantly during CRT at on-RT…

Tweet Image 1
Tweet Image 2

Our paper on First-line pyrotinib in advanced HER2+NSCLC: a patient-centric phase 2 trial rdcu.be/dhCoA. online at Nature Medicine. Thanks Drs. Grant and Goldberg for your comments: "Precise, pragmatic and inclusive: the modern era of oncology clinical trials.

Tweet Image 1
Tweet Image 2

Thomas Wu Reposted

Treatment of patients with HER2-mutant non-small cell lung cancer with pyrotinib in a phase 2 trial or compassionate use showed a favourable objective response rate, while patients treated in parallel by physician's choice in a real-world study did not. nature.com/articles/s4159…


Our review in rdcu.be/dagfs Emerging evidence and treatment paradigm of non-small cell lung cancer

Tweet Image 1

Neoadjuvant SHR-1701 Increases Response, Resectability in Stage III Unresectable NSCLC onclive.com/view/neoadjuva… via @onclive


Did you know IASLC members receive special access to the IASLC’s virtual libraries for all meetings including previous WCLC’s and other IASLC meetings? JOIN or RENEW today! bit.ly/3Fy6otr #LCSM

Tweet Image 1


Thomas Wu Reposted

Did you know IASLC members receive special access to the IASLC’s virtual libraries for all meetings including previous WCLC’s and other IASLC meetings? JOIN or RENEW today! bit.ly/3Fy6otr #LCSM

Tweet Image 1

dailyreporter.esmo.org/esmo-immuno-on… Neoadjuvant PD1-TGF with chemo better than PD1-TGF mono in PD-L1>50% NSCLC and 25.2% surgery conversion in 3A-3C unresectable NSCLC.

Tweet Image 1

ESMO IO Proffered Paper session <small>(ID 21)</small> cslide.ctimeetingtech.com/immuno22hybrid…

Tweet Image 1

Thomas Wu Reposted

Researchers highlighted new #lungcancer study data from around the world during #WCLC22. Catch up on those presentations in ILCN: ow.ly/aKcn50KgltS #LCSM


Consolidation Sugemalimab Provides Sustained PFS Benefit in Unresectable Stage III NSCLC onclive.com/view/consolida… via @onclive The first phase 3 trial showed that sCRT followed by sugemalimab could give stage 3 unresectable patients survival benefit.


Thomas Wu Reposted

🌟ONLINE NOW @LungCaJournal “ “Perioperative targeted therapy for oncogene-driven NSCLC” by @ThomasW35874311 et al #LCSM 🟥Read it here: lungcancerjournal.info/action/showPdf…

Tweet Image 1

Our review Perioperative Target Therapy for Oncogene-Driven NSCLC online on LUNG CANCER

Tweet Image 1

Pembrolizumab Maintains Survival Benefits in 4-year Follow-Up of KEYNOTE-042 in NSCLC in China onclive.com/view/pembroliz… via @onclive


Thomas Wu Reposted

Proud to be involved with this important @myESMO consensus statement. Do check out the section on stage 3 EGFRm NSCLC #LCSM @Annals_Oncology

🆕🌟I’m very proud to share our last manuscript titled “ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell #LungCancer#LCSM A global effort to improve the management of EGFR-positive disease Thanks to all the authors!!! annalsofoncology.org/article/S0923-…

Tweet Image 1


Thomas Wu Reposted

Special thanks to @BostonMagazine for highlighting Dr. Pasi Janne as Top Doctor. We are grateful to have an amazing leader that continues to find the latest research efforts to treat patients with EGFR-Mutant Lung Cancers. bit.ly/3rUAIGp @EGFRResisters @GO2Foundation

Tweet Image 1

Loading...

Something went wrong.


Something went wrong.